Oncolytic virotherapy: new weapon for breast cancer treatment

• Published in: Ecancermedicalscience 2020-12, Vol.14, p.1149-1149
• Main Authors: Martini, Veronica, D'Avanzo, Francesca, Maggiora, Paola Maria, Varughese, Feba Maria, Sica, Antonio, Gennari, Alessandra
• Format: Article
• Language: English
• Subjects: Review
• ISSN: 1754-6605; 1754-6605
• DOI: 10.3332/ECANCER.2020.1149

The recent introduction of viruses as a weapon against cancer can be regarded as one of the most intriguing approaches in the context of precision medicine. The role of immune checkpoint inhibitors has been extensively studied in early and advanced cancer stages, with extraordinary results. Although there is a good tolerability profile, especially when compared with conventional chemotherapy, severe immune-related adverse events have emerged as a potential limitation. Moreover, there are still treatment-resistant cases and thus further treatment options need to be implemented. Several and studies have been conducted and are ongoing to develop oncolytic viruses (OVs) as a tool to modulate the immune system response. OVs are attenuated viruses that can kill cancer cells after having infected them, producing microenvironment remodelling and antitumour immune response. The potential of oncolytic virotherapy is to contrast the absence of T cell infiltrates, converting 'cold' tumours into 'hot' ones, thus improving the performance of the immune system. Breast cancer, the second most common cause of cancer-related deaths among women, is considered a 'cold' tumour. In this context, oncolytic virotherapy might well be considered as a promising strategy. This review summarises the current status, clinical applications and future development of OVs, focusing on breast cancer treatment.